Prognostic impact of histological blood vessel invasion in patients with ampullary adenocarcinoma

Hepato-Gastroenterology

Volumn 57, Issue 104, 2010, Pages 1347-1350

  Kawaguchi, Tsutomu ^a   Ochiai, Toshiya ^a   Ikoma, Hisashi ^a   Inoue, Koji ^a   Morimura, Ryo ^a   Murayama, Yasutoshi ^a   Komatsu, Shuhei ^a   Shiozaki, Atsushi ^a   Kuriu, Yoshiaki ^a   Nakanishi, Masayoshi ^a   Ichikawa, Daisuke ^a   Okamoto, Kazuma ^a   Fujiwara, Hitoshi ^a   Kokuba, Yukihito ^a   Sonoyama, Teruhisa ^a   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Ampullary adenocarcinoma; Histological vessel invasion; Liver metastasis; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD VESSEL INVASION; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DUODENUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PERINEURIUM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AMPULLA OF VATER; COMMON BILE DUCT NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATICODUODENECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR NEOPLASMS;

EID: 79952394938     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Michelassi F, Erroi F, Dawson PJ, Pietrabissa A, Noda S, Handcock M, Block GE: Experience with 647 consecutive tumors of the duodenum, ampulla, head of pancreas, and distal common bile duct. Ann Surg 1989; 210: 544-556. (Pubitemid 19242618)
2. Nagakawa T, Kayahara M, Ikeda S, Futakawa S, Kakita A, Kawarada H, Matsuno M, Takada T, Takasaki K, Tanimura H, Tashiro S, Yamaoka Y: Biliary tract cancer treatment: result from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 2002; 9: 569-575.
3. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe LD, Pitt HA: Periampullary carcinoma: analysis of 5-years survivors. Ann Surg 1998; 227: 821-31.
4. Morris-Stiff G, Alabraba E, Tan YM, Shapey I, Bhati C, Tanniere P, Mayer D, Buckels J, Bramhall S, Mirza DF: Assessment of survival advantage in ampullary carcinoma in relation to tumour biology and morphology. Eur J Surg Oncol. 2009; 35: 746-50.
5. Lowe MC, Coban I, Adsay NV, Sarmiento JM, Chu CK, Staley CA, Galloway JR, Kooby DA: Important prognostic factors in adenocarcinoma of the ampulla of Vater. Am Surg. 2009; 75:754-61.
6. Chan C, Herrera MF, de la Garza L, Quintanilla-Martínez L, Vargas-Vorackova F, Richaud-Patín Y, Llorente L, Uscanga L, Robles-Diaz G, Leon E: Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg 1995; 222: 632-7.
7. Mizuno T, Ishizaki Y, Ogura K, Yoshimoto J, Kawasaki S: Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater. Br J Surg 2006; 93: 221-5. (Pubitemid 43259609)
8. Balachandran P, Sikora SS, Kapoor S, Krishnani N, Kumar A, Saxena R, Kapoor VK: Long-term survival and recurrence patterns in ampullary cancer. Pancreas 2006; 32: 390-5. (Pubitemid 43772195)
9. Cater JT, Grenert JP, Rubenstein L, Stewart L, Way LW: Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg 2008; 207: 210-8.
10. Qiao QL, Zhao YG, Ye ML, Yang YM, Zhao JX, Huang YT, Wan YL: Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007; 31: 137-46.
11. Di Giorgio A, Alfieri S, Rotondi F, Prete F, Di Miceli D, Ridolfini MP, Rosa F, Covino M, Doglietto GB: Pancreatoduodenectomy for tumors of Vater's ampulla: report on 94 consecutive patients. World J Surg 2005; 29: 513-8. (Pubitemid 41125379)
12. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF: Factors predictive of survival in ampullary carcinoma. Ann Surg 1998; 228: 87-94. (Pubitemid 30190320)
13. Todoroki T, Koike N, Morishita Y, Kawamoto T, Ohkohchi N, Shoda J, Fukuda Y, Takahashi H: Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol. 2003; 10: 1176-83. (Pubitemid 40486813)
14. Komatsu S, Sonoyama T, Ochiai T, Ichikawa D, Ikoma H, Okamura H, Otsuji E: Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy. Int J Clin Oncol. 2008; 13: 567-70.
15. Thongprasert S, Napapan S, Charoentum C, Moonprakan S: Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005; 16: 279-81. (Pubitemid 40309310)
16. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K. A: Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer. 2006; 106: 1339-4.
17. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ: Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004; 15: 770-4. (Pubitemid 38714738)
18. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006; 24: 3069-74.